cardiovascular-agents and Movement-Disorders

cardiovascular-agents has been researched along with Movement-Disorders* in 7 studies

Reviews

1 review(s) available for cardiovascular-agents and Movement-Disorders

ArticleYear
Drug therapies for tardive dyskinesia: part 2.
    Journal of psychosocial nursing and mental health services, 2011, Volume: 49, Issue:7

    Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs. No drugs are approved by the U.S. Food and Drug Administration for treating TD. A number of drugs appear to have some benefit for its treatment, including branched-chain amino acids, piracetam (Nootropil(®), Nootrop(®), Nootropyl(®)), clonazepam (Klonopin(®)), levetiracetam (Keppra(®)), propranolol (Inderal(®)), and clonidine (Catapres(®)), and they would be clinically reasonable to try. Gabapentin (Neurontin(®) and others) has a good safety profile and would be appropriate to consider, although no controlled trials confirm its efficacy. The efficacy of ginkgo biloba should be balanced against its safety concerns. Essential fatty acids have not been shown to be effective. Antioxidant therapies, including vitamin E, melatonin, and vitamin B₆, could conceivably be used together with other drug therapies for the treatment of TD.

    Topics: Amino Acids, Branched-Chain; Antioxidants; Cardiovascular Agents; Fatty Acids, Essential; GABA Modulators; Humans; Movement Disorders

2011

Other Studies

6 other study(ies) available for cardiovascular-agents and Movement-Disorders

ArticleYear
[Walking disorder as presentation of inferior acute myocardial infarction in an elderly patient].
    Anales de medicina interna (Madrid, Spain : 1984), 2004, Volume: 21, Issue:8

    Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Heart Function Tests; Humans; Male; Movement Disorders; Myocardial Infarction; Treatment Outcome; Walking

2004
[The use of a new muscle relaxant in the treatment of dyskinetic children].
    Minerva medica, 1962, Jul-14, Volume: 53

    Topics: Cardiovascular Agents; Cerebral Palsy; Child; Humans; Infant; Movement Disorders; Muscle Relaxants, Central

1962
Carisoprodol in the treatment of children with motor difficulties due to brain impairment.
    Archives of pediatrics, 1961, Volume: 78

    Topics: Brain; Cardiovascular Agents; Carisoprodol; Cerebral Palsy; Child; Infant; Movement Disorders; Muscle Relaxants, Central

1961
Clinical evaluation of carisoprodol in handicapped children.
    Annals of the New York Academy of Sciences, 1960, Mar-30, Volume: 86

    Topics: Cardiovascular Agents; Carisoprodol; Child; Disabled Children; Infant; Movement Disorders; Muscle Relaxants, Central

1960
The rationale of treatment of motor disorders with muscle relaxants.
    Annals of the New York Academy of Sciences, 1960, Mar-30, Volume: 86

    Topics: Cardiovascular Agents; Humans; Movement Disorders; Muscle Relaxants, Central; Nervous System Diseases

1960
Hydrogenated ergot alkaloids in treatment of intermittent claudication.
    Canadian Medical Association journal, 1953, Volume: 68, Issue:3

    Topics: Cardiovascular Agents; Dihydroergotoxine; Ergot Alkaloids; Gait; Humans; Intermittent Claudication; Movement Disorders; Oxytocics

1953